Logo Prima Biomed

Key Publications

The publications below are presenting only an excerpt of the various publications that have been released over many years regarding the LAG-3 technology.

LAG-3 Publications

  • Triebel, F., S. Jitsukawa, E. Baixeras, S. Roman-Roman, C. Genevée, E. Viegas-Pequignot, and T. Hercend. 1990. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171:1393.
  • Huard, B., R. Mastrangeli, P. Prigent, D. Bruniquel, S. Donini, N. El-Tayar, B. Maigret, M. Dreano, and F. Triebel. 1997. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc. Natl. Acad. Sci. USA 94:5744.
  • Prigent, P., S. E. Mir, M. Dreano, and F. Triebel. 1999. LAG-3 induces tumor regression and antitumor immune responses in vivo. Eur. J. Immunol. 29:3867.
  • Triebel, F. 2003. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 24:619.
  • Triebel, F., K. Hacene, and M. F. Pichon. 2006. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 235:147.
  • Brignone, C., C. Grygar, M. Marcu, K. Schakel, and F. Triebel. 2007. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol 179:4202.
  • Brignone, C., B. Escudier, C. Grygar, M. Marcu, and F. Triebel. 2009. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15:6225.
  • Brignone, C., M. Gutierrez, F. Mefti, E. Brain, R. Jarcau, F. Cvitkovic, N. Bousetta, J. Medioni, J. Gligorov, C. Grygar, M. Marcu, and F. Triebel. 2010. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8:71.